Regeneron Pharmaceuticals

REGNintermediary

Regeneron is a leading biotechnology company built on its proprietary VelociSuite antibody-discovery platform. Dupixent has become one of the best-selling drugs globally, and the company's deep pipeline of bispecific antibodies and next-gen immunotherapies positions it for continued growth beyond its current blockbusters.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($16.2B)

靜態數據（加載即時財務…）

Dupixent (net collaboration) (52%)

Eylea (U.S.) (25%)

Oncology (Libtayo) (10%)

Other Products & Collaboration (13%)

業務部門構成與主要客戶

產品詳情

Dupixent (dupilumab)52%

IL-4/IL-13 antibody for atopic dermatitis, asthma, COPD, and allergic conditions

Eylea / Eylea HD25%

Anti-VEGF injection for wet AMD and diabetic eye disease

Libtayo (cemiplimab)8%

PD-1 checkpoint inhibitor for skin and lung cancers

Kevzara (sarilumab)3%

IL-6 receptor antibody for rheumatoid arthritis

Antibody Pipeline (bispecifics, LAG-3)12%

Next-generation bispecific antibodies and combination cancer immunotherapies

供應鏈關係

競爭對手

Eli Lilly and Company

Immunology, antibody therapies

影響: Competing in biologics

Moderna, Inc.

Cancer immunotherapy

影響: Competing in oncology

Novo Nordisk

Metabolic disease overlap

影響: Limited overlap

合作夥伴

Pfizer Inc.

Potential collaboration

影響: Collaborative pipeline

宏觀與市場背景

제약 / 바이오行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化劑

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

供應鏈問題

★ 기회Dupixent 적응증 10개 돌파 — 최대 블록버스터 예약

2026-04

COPD 추가 FDA 승인으로 Dupixent 총 적응증 10개. 2030년 $20B 매출 전망으로 글로벌 최대 단일 의약품 등극 예상.

↑ 생산 확대아일랜드 리머릭 바이오 제조시설 확충

2026-03

Dupixent 수요 급증 대비 아일랜드 공장 bioreactor 20만리터 추가. 2027년 완공, 생산 병목 해소.

AI 分析

點擊「取得 AI 分析」以獲得 Regeneron Pharmaceuticals 的 AI 供應鏈分析。

企業資訊

總部

Tarrytown, New York, USA

成立時間

1988

員工人數

14,000+

官網

regeneron.com

連鎖位置

連鎖中的角色

late mover

典型延遲

2-5 trading days

Regeneron's antibody platform may produce GLP-1 alternatives; the company reacts to obesity-market sizing and competitive dynamics.

檢視完整連鎖分析

行業概況 — 제약 / 바이오

行業新聞